Here's a roundup of top developments in the biotech space over the last 24 hours:
(Biotech Stocks Hitting 52-week Highs Nov. 11)
(Biotech Stocks Hitting 52-week Lows Nov. 11)
Inhibrx Inc (NASDAQ:INBX) announced updated interim results from the Phase 1 study of INBRX-109 in patients with chondrosarcoma, showing of the 12 evaluable patients, disease control was observed in 11 patients, with eight of the 12 patients seeing a decrease in tumor burden. As of October, two of the patients achieved partial responses, with reduction in tumor size of 60% and 32%.
"We believe the results in chondrosarcoma, a disease with a significant unmet need, are very promising," said CEO Mark Lappe.
The company said it plans to meet with the FDA in the near future to discuss the design of a registration-enabling study that's likely to commence in the second quarter of 2021.
The stock rallied 10.31% to $21.18 in after-hours trading.
Five Prime presented at the Society for Immunotherapy of Cancer, SITC, conference preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors.
The data showed that the investigational immunotherapy FPA157 elicits anti-tumor activity in multiple preclinical models.
Separately, the company said it plans to offer 5 million shares of its common stock in an underwritten public offering.
The stock was up 15.78% at $20.84 premarket Thursday.
Xencor Inc (NASDAQ:XNCR), Morphosys Ag (NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and Bristol-Myers Squibb Co's (NYSE:BMY) Revlimid in patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, first-line DLBCL and relapsed or refractory follicular lymphoma.
Under the terms of the agreement, the companies initially plan to initiate a Phase 1/2 study evaluating the combo in patients with relapsed or refractory DLBCL. Additionally, the companies are planning to evaluate the combo in relapsed or refractory FL and first-line DLBCL in multiple Phase 1b studies.
MorphoSys and Incyte will provide tafasitamab for the studies, which will be sponsored and funded by Xencor and conducted in North America, Europe and Asia-Pacific.
In premarket trading Thursday, Morphosys shares were slipping 3.06% to $25.66, while Incyte was adding 1.47% to $83.98.
AstraZeneca plc (NASDAQ:AZN) said its ALAVI Phase 2 trials for Calquence in patients hospitalized with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care did not increase the proportion of patients who remained alive and free of respiratory failure, the company said.
The stock was edging down 1.02% to $57.43 in premarket trading.
Related Link: The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
Qiagen NV (NYSE:QGEN) said it has started commercialization of a portable digital test in the U.S. that can be used by labs to detect SARS-CoV-2 antigens in people with active infections in 2-15 minutes. A point of care claim will be added and emergency use authorization amended later this year, the company said.
In premarket trading, the stock was 1.35% higher at $47.14.
Earnings
PDL BioPharma Inc (NASDAQ:PDLI) reported revenue of $4.12 million for the two months ended Aug. 31, 2020 compared to $8.03 million for the three months ended Sept. 30, 2019. The company reversed from a loss of 16 cents per share to a profit of 4 cents per share.
The company said it plans to file a certificate of dissolution with the State of Delaware Jan. 4, 2021, with the stock expected to be delisted from the Nasdaq after Dec. 31.
The stock was up 3.98% premarket at $2.35.
OpGen Inc's (NASDAQ:OPGN) third-quarter revenue climbed from $648,220 in 2019 to $1.057 million in 2020. The loss per share narrowed from $3.95 to 40 cents. Analysts had estimated a loss of 36 cents per share.
The stock was up 4.37% at $2.39 premarket.
Cue Biopharma Inc (NASDAQ:CUE) is due to make a poster presentation on Phase 1 study of CUE-101 in patients with recurrent/metastatic HPV16+ head and neck cancer.
Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。